Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | CA3 | P07451 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 2/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736707 | 0.86 | EPHX1 (0.84) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL1389225 | 0.84 | EPHX1 (0.96) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL13861685 | 0.84 | ALDH1A1 (0.79) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL7539898 | 0.83 | CA3 (0.78) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL5988047 | 0.83 | EPHX1 (0.50) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL10690536 | 0.82 | EPHX1 (1.00) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL7716931 | 0.82 | EPHX1 (1.00) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL10688529 | 0.82 | EPHX1 (1.00) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL13010044 | 0.82 | EPHX1 (1.00) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL10683800 | 0.82 | EPHX1 (1.00) | EPHX1ALDH1A1POLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197879-B1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS INC (US) | 2014-01-22 | — | — | EP | claimed |
| EP-2197879-A1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-06-23 | — | — | EP | claimed |
| US-7687496-B2 | C7-substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2010-03-30 | — | — | US | claimed |
| WO-2009051580-A1 | C7-SUBSTITUTED CAMPTOTHECIN ANALOGS | BIONUMERIK PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | WO | claimed |
| US-20090099224-A1 | C7- substituted camptothecin analogs | BIONUMERIK PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| CN-118165071-A | Oxo-spiro indoline compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118084996-A | Reversible termination nucleotide and application thereof in DNA synthesis sequencing and single molecule sequencing | 上海交通大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| US-20230387464-A1 | Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery | MU IONIC SOLUTIONS CORPORATION (JP) | 2023-11-30 | — | — | US | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023083194-A1 | WEE1 PROTEIN KINASE DEGRADATION AGENT AND USE THEREOF | 杭州格博生物医药有限公司 | 2023-05-19 | — | — | WO | disclosed |
| EP-0773026-A2 | NK-1 receptor antagonists for the treatment of cancer | PFIZER INC. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5569662-A | ANTIINFLAMMATORY AGENT, GASTROINTESTINAL DISORDERS, NERVOUS SYSTEM DISORDERS, ANTIASTHMA AGENTS, ANALGESICS | PFIZER INC. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5449602-A | Polynucleotides | AMOCO CORPORATION (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0324616-B1 | Template-directed photoligation | AMOCO CORP (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0324616-A2 | Template-directed photoligation | AMOCO CORPORATION (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4719312-A | FLUOROALKYLAMINES | MERCK & CO., INC. (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0009944-B1 | LYSOSOMOTROPIC FLUORINATED AMINE THERAPEUTIC AGENTS AND COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1983-05-18 | — | — | EP | disclosed |
| EP-0009944-A2 | Lysosomotropic fluorinated amine therapeutic agents and compositions containing them | MERCK & CO. INC. (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099224-A1 | C7- substituted camptothecin analogs | ABCB1, ABCC1, ABCG2 | EPHX1 2043/4885ALDH1A1 979/4885POLB 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.